Oxacom
Small molecule
Oxacom is one of 41 small molecule programs targeting Pulmonary Arterial Hypertension. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
179 competitors in Pulmonary Arterial Hypertension
#DrugCompanyPhaseTrials
1Gleevec
NovartisPhase 3
Reata
BiogenPhase 3
Levitra
BayerPhase 3
Aurlumyn
BBTG International Inc.
Phase 3
Flolan
Johnson & JohnsonPhase 3
Zesly
MMezzion Pharma Co. Ltd
Phase 3
Atrovent
Boehringer IngelheimPhase 3
Inhaled Iloprost
BayerPhase 3
Farxiga
AstraZenecaPhase 2
Rituxan
RochePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Oxacom. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]